Guilin Sanjin Pharmaceutical Co., Ltd.

SZSE:002275.SZ

14.38 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 2,171.7491,959.7331,741.2251,566.4851,640.4241,584.6731,616.0161,525.2241,371.8211,466.3521,452.6361,311.5471,161.781983.461,110.829986.158893.048797.852
Cost of Revenue 586.402568.781447.097448.861445.256432.426389.259410.211376.907415.12395.814387.798330.975272.086255.068253.361243.994238.081
Gross Profit 1,585.3471,390.9521,294.1271,117.6241,195.1681,152.2481,226.7571,115.013994.9151,051.2321,056.822923.749830.806711.374855.76732.797649.054559.771
Gross Profit Ratio 0.730.710.7430.7130.7290.7270.7590.7310.7250.7170.7280.7040.7150.7230.770.7430.7270.702
Reseach & Development Expenses 158.062217.036202.45154.282104.11264.66653.88337.59131.02622.19512.8470000000
General & Administrative Expenses 68.85762.58941.46239.18431.18329.41633.93525.75424.16322.86239.28339.24935.45829.03488.98276.95976.70872.038
Selling & Marketing Expenses 717.857538.344564.953497.476498.241452.627497.972491.395443.553418.036462.928411.274369.401299.08375.503306.242265.479246.615
SG&A 786.714600.933606.415536.66529.424482.043531.908517.15467.715440.897502.211450.523404.858328.114464.485383.201342.187318.653
Other Expenses -1,655.144164.58175.28590.69694.942-2.572-1.67513.13417.4267.83829.2357.7992.4363.8387.4390.9089.4320.784
Operating Expenses 1,655.144982.551884.151781.638728.478653.866687.719664.845594.699551.591590.346537.229491.841412.065481.431397.947354.879329.933
Operating Income 516.605446.781429.035354.739469.416498.258564.66467.342423.007523.435484.623398.578362.709312.848369.952326.726289.177230.47
Operating Income Ratio 0.2380.2280.2460.2260.2860.3140.3490.3060.3080.3570.3340.3040.3120.3180.3330.3310.3240.289
Total Other Income Expenses Net -0.438-0.6010.023-10.574-1.78-2.69623.94829.39940.08731.55846.73619.78626.1817.3283.062-7.2923.6431.393
Income Before Tax 516.168446.18429.058344.165467.636495.686562.985479.566440.303531.198513.212406.306365.145316.637377.391327.559297.818231.23
Income Before Tax Ratio 0.2380.2280.2460.220.2850.3130.3480.3140.3210.3620.3530.310.3140.3220.340.3320.3330.29
Income Tax Expense 96.985116.65385.33967.14475.49382.3498.58385.90663.6386.33292.94475.15573.24659.25469.55953.4748.3236.214
Net Income 421.299329.527343.719277.021392.143413.346464.402393.66376.673444.866420.268331.152291.954258.758307.315273.727249.178194.804
Net Income Ratio 0.1940.1680.1970.1770.2390.2610.2870.2580.2750.3030.2890.2520.2510.2630.2770.2780.2790.244
EPS 0.670.560.60.480.670.70.790.670.640.750.710.560.490.440.550.520.470.37
EPS Diluted 0.720.560.60.480.670.70.790.670.640.750.710.560.490.440.550.520.470.37
EBITDA 663.075559.341556.318432.253564.012578.798634.297549.708500.383574.176543.73440.793393.244342.583398.113358.964318.981250.643
EBITDA Ratio 0.3050.2850.3190.2760.3440.3650.3930.360.3650.3920.3740.3360.3380.3480.3580.3640.3570.314